Today: 21 May 2026
Ripple Says ‘No IPO’ — $40B Valuation, $500M Round, and Mastercard RLUSD Pilot Define Its 2026 Game Plan (Nov. 6, 2025)
6 November 2025
3 mins read

Ripple Says ‘No IPO’ — $40B Valuation, $500M Round, and Mastercard RLUSD Pilot Define Its 2026 Game Plan (Nov. 6, 2025)

NEW YORK — Ripple is shutting the IPO window for now. At the company’s Swell conference this week, President Monica Long said there is “no plan, no timeline” to take Ripple public, even as the firm locks in fresh capital, expands payments with its RLUSD stablecoin, and steps up acquisitions. Bloomberg

What’s new today

  • No IPO in sight. Long reiterated that Ripple will remain private in the near term. The comments were made at Swell in New York on Nov. 5.
  • Fresh funding, bigger war chest. Ripple closed a $500 million strategic investment that values the company at $40 billion—a round led by Fortress Investment Group and Citadel Securities.
  • Stablecoin push with card networks. Ripple, Mastercard, WebBank, and Gemini are piloting settlement of fiat card transactions using Ripple’s RLUSD on the XRP Ledger—an effort that, if successful, would be among the first times a regulated U.S. bank settles traditional card payments via a regulated stablecoin on a public blockchain.

Why Ripple is skipping an IPO for now

Ripple says it doesn’t need public-market capital to fund growth, pointing instead to a strengthening balance sheet and investor demand in private markets. Long’s “no plan, no timeline” stance underscores a private‑first strategy while the company focuses on expanding payments, custody, and prime brokerage alongside RLUSD adoption. Bloomberg

Regulatory tailwinds also factor in: the GENIUS Act—a new U.S. framework for stablecoins—has accelerated institutional interest in regulated stablecoins for treasury and collateral use cases, a trend Ripple says it is positioned to capture.


Follow the money: $500M at a $40B valuation

Ripple’s latest round brings heavyweight traditional‑finance names—Fortress and Citadel Securities—onto its cap table. The company framed the raise as strategic (not a liquidity lifeline), aligning new investors with its payments and stablecoin roadmap. In its announcement, Ripple highlighted $95B+ total payments volume, 75 regulatory licenses, and RLUSD’s rapid growth.

Separately, the Financial Times also reported the round and $40B valuation, contextualizing how stablecoin infrastructure has become a favored bet for large funds.


The payments angle: RLUSD + Mastercard pilot

The pilot with Mastercard, WebBank (issuer of the Gemini Credit Card), and Gemini aims to test settling card transactions using RLUSD on XRPL. If implemented at scale, it could shrink settlement times and operating frictions in traditional card flows—without abandoning regulatory compliance. CoinDesk and DL News report the trial could be among the first of its kind involving a regulated U.S. bank and a regulated stablecoin on a public chain.


M&A blitz: building a full‑stack institutional platform

Ripple has been buying capabilities to round out an institutional product suite:

  • Hidden Road (prime brokerage) — a $1.25B deal announced in April that brings multi‑asset prime services and has since operated as “Ripple Prime.” Reuters
  • Rail (stablecoin payments infrastructure) — a $200M acquisition disclosed in August to enhance cross‑border stablecoin flows and virtual accounts.
  • GTreasury (treasury management system) — a $1B purchase announced Oct. 16, opening Ripple to the corporate treasury market and its Fortune‑500 customer base (confirmed by seller Hg and industry trade reports).

These moves knit together payments, custody, stablecoin issuance (RLUSD), and prime brokerage under one roof—giving enterprises a compliant, 24/7 stack for moving and managing money. Ripple’s latest press materials say RLUSD has now surpassed $1B in circulation and is already used as collateral within Ripple Prime.


By the numbers

  • Valuation: $40B (post‑money)
  • New capital: $500M strategic investment
  • Payments volume: $95B+ (lifetime across Ripple Payments)
  • Licensing: 75 regulatory licenses
  • Stablecoin: RLUSD >$1B circulating supply (split across XRPL and Ethereum)
    Source: Ripple press release; Reuters coverage.

What to watch next

  • Pilot outcomes: Will the Mastercard–WebBank–Gemini pilot move from proof‑of‑concept to production settlement rails?
  • Regulatory scope: How will U.S. stablecoin rules (GENIUS Act) and bank‑charter ambitions shape RLUSD’s role in corporate treasury and card settlement? (Ripple applied for a U.S. national bank charter earlier this year.)
  • Further M&A: With fresh capital and momentum, additional tuck‑ins around payments, custody, or compliance tech would be consistent with Ripple’s 2025 playbook.

Context & coverage from today (Nov. 6, 2025)

  • Bloomberg first reported the “no plan, no timeline” line from President Monica Long at Swell in New York. Bloomberg
  • Parameter and Coinfomania carried follow‑ups today echoing the “no IPO” stance and highlighting the focus on RLUSD and acquisitions. Parameter+1

Quick FAQ

Is Ripple planning an IPO?
Not now. Ripple’s president says there is no plan and no timeline for a listing.

Why raise private money if not going public?
Ripple framed the $500M as strategic capital from blue‑chip investors to deepen partnerships and accelerate its stablecoin/payments roadmap without the constraints of public markets.

What exactly is RLUSD?
Ripple’s U.S. dollar–backed stablecoin used across its payments stack and pilots; it recently crossed $1B in circulation.

What’s the significance of the Mastercard pilot?
If it scales, it could be among the first instances of a U.S. regulated bank settling traditional card payments with a regulated stablecoin on a public blockchain.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
NYSE Skyrockets to Record Highs as AI Frenzy, Fed Rate Cut Bets Fuel Stock Surge
Previous Story

Stocks to Sell Today (Nov 6, 2025): e.l.f. Beauty, Duolingo, DoorDash, Super Micro, Meta, Palantir—and Airline Majors Under FAA Cuts

Tesla’s Stock Skyrockets on AI Hype – Latest Price Jump, Earnings Shocks & Bold 2025 Forecasts
Next Story

Tesla (TSLA) Today: Shareholders Vote on Musk’s Record Pay, Cybertruck Lineup Shifts—What It Means for the Stock (Nov. 6, 2025)

Go toTop